Galapagos are developing new potentiators that have a superior effect on CFTR opening than Kalydeco. The superior opening was seen with class 2, 3 and 4 mutations. It is planned to start a trial by the end of 2014.

New correctors are also being developed in colloboration with AbbVie. It is planned to have a corrector in trials by the end of 2015.


Galapagos are developing new CFTR potentiators and correctors.

The attached image suggests that there is superior CFTR opening with their potentiator compared to Kalydeco with F508del and that GLPG1 may be more potent with G551D than Kalydeco.

Click on the title to read more